Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

1.75
+0.13008.02%
Volume:692.37K
Turnover:1.21M
Market Cap:67.31M
PE:-2.75
High:1.82
Open:1.63
Low:1.63
Close:1.62
52wk High:4.34
52wk Low:1.41
Shares:38.46M
Float Shares:37.12M
Volume Ratio:1.19
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6370
EPS(LYR):-0.8920
ROE:-261.72%
ROA:-86.79%
PB:11.39
PE(LYR):-1.96

Loading ...

Company Profile

Company Name:
Gain Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
24
Office Location:
4800 Montgomery Lane,Suite 220,Bethesda,Maryland,United States
Zip Code:
20814
Fax:
- -
Introduction:
Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Directors

Name
Position
Gene Mack
President, Chief Executive Officer and Director
Khalid Islam
Founder and Chairman of the Board
Claude Nicaise
Director
Dov Goldstein
Director
Gwen Melincoff
Director
Hans Peter Hasler
Director
Jeffrey Riley
Director

Shareholders

Name
Position
Gene Mack
President, Chief Executive Officer and Director
Gianluca Fuggetta
Senior Vice President Finance, Principal Financial Officer